European Journal of Nuclear Medicine and Molecular Imaging最新文献

{"title":"Striatal dopamine transporter uptake predicts neuronal hypometabolism and visuospatial function in Parkinson's disease.","authors":"Seungbeom Seo, Yeo Jun Yoon, Sangwon Lee, Hyunkeong Lim, Kyobin Choo, Daesung Kim, Hyunkyung Han, Seongjin Kang, Jaekyung Park, Phil Hyu Lee, Dongwoo Kim, Mijin Yun","doi":"10.1007/s00259-025-07137-x","DOIUrl":"10.1007/s00259-025-07137-x","url":null,"abstract":"<p><strong>Purpose: </strong>While many studies have explored the link between biomarkers and cognitive decline in Parkinson's disease (PD), a more comprehensive approach is needed, combining striatal dopamine depletion, cerebral glucose metabolism, and cognitive assessments. In this study, we investigated the relationships between striatal dopamine transporter (DAT) uptake, cerebral glucose hypometabolism, and cognition, as well as the potential progression pattern of these changes in PD.</p><p><strong>Methods: </strong>We enrolled 62 patients with PD and 33 healthy controls. The subjects underwent N-(3-[¹⁸F]fluoropropyl)-2β-carbomethoxy-3β-(4-iodophenyl)nortropane (FP-CIT) PET/CT, [¹⁸F] fluorodeoxyglucose (FDG) PET/CT, and detailed neuropsychological testing. The mean standard uptake value ratio (SUVR) value of the regions showing significantly lower metabolism in PD patients was defined as SUVR_[hypo]. The relationship between striatal DAT uptake and SUVR_[hypo] was assessed using general linear models, while their impact on cognitive function was evaluated with multivariate linear regression. Additionally, the pattern of their changes was assessed using an event-based model.</p><p><strong>Results: </strong>Compared to the control group, PD patients exhibited glucose hypometabolism in specific cortical regions. DAT uptake in the anterior and posterior putamen was positively correlated with SUVR_[hypo]. Decreased DAT uptake in the anterior putamen and caudate nucleus was associated with lower z-score in visuospatial function. Decreased DAT uptake in the posterior and anterior putamen occurred first, followed by PD-related cerebral hypometabolism, and visuospatial function.</p><p><strong>Conclusion: </strong>This study highlights the interconnectedness of dopaminergic depletion, cerebral glucose hypometabolism, and visuospatial dysfunction, proposing that striatal DAT uptake may serve as an early biomarker for cerebral hypometabolism and cognitive impairment in PD.</p>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":" ","pages":"2307-2316"},"PeriodicalIF":8.6,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143413649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Biodistribution and dosimetry of [¹⁷⁷Lu]Lu-SibuDAB in patients with metastatic castration-resistant prostate cancer.","authors":"Philipp Ritt, René Fernández, Cristian Soza-Ried, Heinz Nicolai, Horacio Amaral, Korbinian Krieger, Ana Katrina Mapanao, Amanda Rotger, Konstantin Zhernosekov, Roger Schibli, Cristina Müller, Vasko Kramer","doi":"10.1007/s00259-025-07102-8","DOIUrl":"10.1007/s00259-025-07102-8","url":null,"abstract":"<p><strong>Purpose: </strong>Several prostate-specific membrane antigen (PSMA) radiopharmaceuticals have been used for the treatment of metastatic, castration-resistant prostate cancer (mCRPC). In an attempt to improve the tumour accumulation, new PSMA ligands were developed with an albumin-binding entity to enhance the blood circulation and, hence, tumour accumulation. In preclinical studies, [¹⁷⁷Lu]Lu-SibuDAB, a radiopharmaceutical with moderate albumin-binding properties, outperformed [¹⁷⁷Lu]Lu-PSMA-617 and [¹⁷⁷Lu]Lu-PSMA-I&T. The aim of this study was to evaluate the dosimetry of [¹⁷⁷Lu]Lu-SibuDAB in patients diagnosed mCRPC.</p><p><strong>Methods: </strong>Seventeen patients (median age 72 years, range 63‒83) diagnosed with progressive disease of mCRPC were included in this prospective study after exhausting all available treatment options. They were injected with 5.3 ± 0.5 GBq (mean ± standard deviation) [¹⁷⁷Lu]Lu-SibuDAB as a first treatment cycle. Sixteen of these patients underwent sequential whole-body SPECT/CT and activity determination in venous blood samples for dosimetry purposes. Absorbed doses to the salivary glands, liver, spleen, kidneys, and red marrow as well as selected tumour lesions were calculated in OLINDA/EXM™ and compared to published values for previously established PSMA radiopharmaceuticals.</p><p><strong>Results: </strong>Absorbed dose coefficients (ADC) to tumours (9.9 ± 5.4 Gy/GBq) were about 2-fold higher than those reported for clinically approved PSMA radiopharmaceuticals. ADC to salivary glands, liver, spleen, kidneys and red marrow were higher (0.5 ± 0.2, 0.2 ± 0.05, 0.2 ± 0.1, 1.8 ± 0.6, 0.1 ± 0.04 Gy/GBq, respectively) than for [¹⁷⁷Lu]Lu-PSMA-617 and [¹⁷⁷Lu]Lu-PSMA-I&T, but lower than for [¹⁷⁷Lu]Lu-PSMA-ALB-56, a previously investigated long-circulating PSMA radiopharmaceutical. The tumour-to-kidneys, tumour-to-red marrow, tumour-to-salivary glands ADC ratio were 6.6, 102, 33.1. These ratios were comparable to those of [¹⁷⁷Lu]Lu-PSMA-617 and [¹⁷⁷Lu]Lu-PSMA-I&T for kidneys and red-marrow, but higher for salivary glands.</p><p><strong>Conclusion: </strong>[¹⁷⁷Lu]Lu-SibuDAB showed a prolonged blood circulation time and, hence, a significantly increased absorbed tumour dose, while tumour-to-organ ADC ratios were similar to conventional PSMA radiopharmaceuticals. Further clinical investigations to evaluate the efficacy and safety of [¹⁷⁷Lu]Lu-SibuDAB are, thus, warranted.</p>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":" ","pages":"2431-2443"},"PeriodicalIF":8.6,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143079082","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Head-to-Head comparison of [¹⁸F]FDG, [¹⁸F]FMZ, and [¹⁸F]SynVesT-1 positron emission tomography imaging in patients with drug-resistant epilepsy.","authors":"Guanglei Li, Zengping Lin, Weiqi Bao, Shize Jiang, Jie Wang, Qi Huang, Yang Yang, Juanjuan He, Yiyun Huang, Yihui Guan, Jie Hu, Fang Xie","doi":"10.1007/s00259-025-07111-7","DOIUrl":"10.1007/s00259-025-07111-7","url":null,"abstract":"<p><strong>Purpose: </strong>The loss of synaptic vesicle glycoprotein 2 A (SV2A) can lead to dysfunction of GABAergic neurons, but a direct comparison of SV2A and GABA_A receptor densities in humans has not been assessed. This study evaluated SV2A and GABA_A receptor abnormalities in patients with drug-resistant epilepsy (DRE) and compared the patterns to glucose hypometabolism.</p><p><strong>Methods: </strong>Eleven patients with DRE were retrospectively recruited and underwent PET imaging with [¹⁸F]fluorodeoxyglucose ([¹⁸F]FDG), [¹⁸F]Flumazenil (FMZ), and [¹⁸F]SynVesT-1. Visual assessments counted abnormal metabolic brain regions based on the Anatomical Automatic Labeling (AAL) atlas, while voxel-level analyses delineated the abnormal metabolic distributions. The relationship between hypo-metabolic distributions and the age of epilepsy onset was analyzed.</p><p><strong>Results: </strong>The hypometabolic regions in [¹⁸F]FDG PET, identified in the AAL atlas, was significantly broader than in [¹⁸F]FMZ (p = 0.0005) and [¹⁸F]SynVesT-1 (p = 0.0010) PET, with no statistical difference observed between [¹⁸F]FMZ and [¹⁸F]SynVesT-1 PET (p > 0.05). The voxel number in [¹⁸F]FDG PET was significantly higher than that of the [¹⁸F]FMZ and [¹⁸F]SynVesT-1 PET in both hypo-intensity area and severe hypo-intensity area. The ratio of the voxel number between these two area was higher for [¹⁸F]SynVesT-1 PET compared to [¹⁸F]FDG PET (p = 0.0195) and [¹⁸F]FMZ PET (p = 0.0237), and positively correlated with the age of epilepsy onset (r = 0.7397, p = 0.0145).</p><p><strong>Conclusions: </strong>[¹⁸F]FMZ and [¹⁸F]SynVesT-1 PET images revealed a more restricted pattern of reduced uptake compared to [¹⁸F]FDG PET in DRE patients. The age of epilepsy onset correlated with a reduction in [¹⁸F]SynVesT-1 uptake but not in [¹⁸F]FMZ or [¹⁸F]FDG uptake.</p>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":" ","pages":"2258-2266"},"PeriodicalIF":8.6,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143064706","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development and biological evaluation of a novel CEACAM6-targeted PET tracer for distinguishing malignant nodules in early-stage lung adenocarcinoma.","authors":"Keying Zhu, Shimin Tang, Donghui Pan, Xinyu Wang, Yuping Xu, Junjie Yan, Lizhen Wang, Chongyang Chen, Min Yang","doi":"10.1007/s00259-025-07107-3","DOIUrl":"10.1007/s00259-025-07107-3","url":null,"abstract":"<p><strong>Purpose: </strong>Low-dose CT (LDCT) screening effectively reduces lung adenocarcinoma (LUAD) mortality. However, accurately evaluating the malignant potential of indeterminate lung nodules remains a challenge. Carcinoembryonic antigen cell adhesion molecule 6 (CEACAM6), a potential biomarker for distinguishing benign pulmonary nodules from LUAD, may be leveraged for noninvasive positron emission tomography (PET) imaging to aid LUAD diagnosis.</p><p><strong>Methods: </strong>This study utilized mRNA, protein, and survival datasets of LUAD patients, along with an animal model of malignant pulmonary nodules, to investigate CEACAM6 expression specificity and its correlation with LUAD. Targeting ligands for CEACAM6 were designed using the Rosetta platform, labeled with [⁶⁸Ga]Ga, and screened through high-throughput PET imaging to identify the optimal tracer.</p><p><strong>Results: </strong>CEACAM6 was found to be specifically overexpressed in LUAD and was significantly associated with poor prognosis and disease progression. In vivo, [⁶⁸Ga]Ga-NODA-P3 demonstrated high specificity for delineating CEACAM6-positive A549 xenografts, a LUAD model, via PET imaging, achieving a highest target-to-background ratio of 7.68 ± 0.44. Region of interest (ROI) analysis showed significantly higher tracer uptake in A549 xenografts compared to CEACAM6-negative Huh7 xenografts (a hepatocellular carcinoma model) at 30 min post-injection (1.81 ± 0.10%ID/g vs. 0.54 ± 0.06%ID/g). Pre-treatment with an excess of unlabeled NODA-P3 significantly reduced tumor uptake to 0.52 ± 0.07%ID/g.</p><p><strong>Conclusion: </strong>These preclinical findings indicate that [⁶⁸Ga]Ga-NODA-P3 is a candidate radiotracer for the non-invasive visualization of CEACAM6-positive LUAD, demonstrating favorable imaging contrast. Although the current tumor uptake limits its immediate clinical application, ongoing optimization efforts are expected to improve its efficacy, enabling earlier and more accurate diagnosis of malignant pulmonary nodules in LUAD.</p>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":" ","pages":"2414-2430"},"PeriodicalIF":8.6,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143064704","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Leveraging small voxel with optimal acquisition time for [¹⁸F]mFBG total-body PET/CT imaging in pediatric patients with neuroblastoma: a preliminary study.","authors":"Zhaoting Cheng, Xiaoyun Deng, Shuang Song, Yang Wu, Hongmei Tang, Sijuan Zou, Yuankai Zhu, Aiguo Liu, Xiaohua Zhu","doi":"10.1007/s00259-025-07098-1","DOIUrl":"10.1007/s00259-025-07098-1","url":null,"abstract":"<p><strong>Purpose: </strong>The advent of total-body PET/CT presents an opportunity for significant advancements in imaging of neuroblastoma with [¹⁸F]meta-fluorobenzylguanidine ([¹⁸F]mFBG). Small voxel imaging has proven to have better lesion detectability but need enough radioactivity counts. This study aims to balance shortened acquisition times and small voxel reconstruction to keep sufficient image quality and diagnostic confidence on [¹⁸F]mFBG total-body PET for neuroblastoma.</p><p><strong>Methods: </strong>We retrospectively enrolled 33 pediatric patients with neuroblastoma who underwent 37 [¹⁸F]mFBG total-body uEXPLORER PET/CT scans of 10-min duration. PET images were reconstructed with varying acquisition times (0.5-10 min) and three matrix sizes (192 × 192, 512 × 512 and 1024 × 1024). The subjective (scored on a 5-point scale) and objective image quality (signal-to-noise ratio, SNR) of all the sets of reconstructed images were analyzed by nuclear medicine physicians. For indeterminate lesions identified in the group of 192 × 192 matrix with the 10-min scan (G192-10), diagnostic confidence was further evaluated in images reconstructed with the 512 × 512 and 1024 × 1024 matrices (G512 and G1024).</p><p><strong>Results: </strong>Of the 33 patients with 37 [¹⁸F]mFBG PET/CT scans, 17 patients with 20 scans had positive [¹⁸F]mFBG PET/CT findings. Sufficient subjective image quality was achieved with at least 2-min acquisition of 192 × 192 matrix and 4-min acquisition of 512 × 512 matrix (with all scores ≥ 3). SNR increased with longer acquisition times for the same voxel size, while decreased as voxel size shrunk. Although the Curie and SIOPEN scores remained consistent across G192, G512, and G1024-10 groups, the G512 groups with at least 2-min acquisition and G1024-10 showed significantly higher confidence scores for characterizing indeterminate lesions on the G192-10 images, with almost all indeterminate lesions being rated as very confident.</p><p><strong>Conclusions: </strong>A matrix of 512 × 512 with a minimum of 4-min acquisition on [¹⁸F]mFBG total-body PET/CT is recommended for sufficient image quality and improved diagnostic confidence, particularly in detecting indeterminate lesions.</p>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":" ","pages":"2397-2413"},"PeriodicalIF":8.6,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143064710","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Whole-body PET imaging of simian immunodeficiency virus using gp120-targeting probes fails to reveal regions of specific uptake in rhesus macaques.","authors":"Sharat Srinivasula, Insook Kim, Hyukjin Jang, Paula Degrange, Heather Brown, Viviana Dalton, Yunden Badralmaa, Ven Natarajan, Brad Long, Jorge A Carrasquillo, Michele Di Mascio","doi":"10.1007/s00259-025-07110-8","DOIUrl":"10.1007/s00259-025-07110-8","url":null,"abstract":"<p><strong>Purpose: </strong>Following the initial reports demonstrating the feasibility of immunoPET imaging of simian immunodeficiency virus (SIV) using gp120-targeting monoclonal antibodies in non-human primates, replication efforts of the imaging system in human immunodeficiency virus (HIV)-infected individuals have yielded conflicting results. Herein, we used two anti-gp120 antibodies, 7D3 and ITS103.01LS-F(ab')₂, to interrogate the reproducibility of gp120-targeting probes for immunoPET imaging of SIV in rhesus macaques.</p><p><strong>Methods: </strong>The binding affinity estimates of ⁸⁹Zr radiolabeled 7D3 and ITS103.01LS-F(ab')₂ to SIV gp120, and the in-vitro and ex-vivo binding specificities of [⁸⁹Zr]Zr-7D3 and [⁸⁹Zr]Zr-ITS103.01LS-F(ab')₂ to SIV Env expressing cells, primary cells, and tissue sections from uninfected and SIV-infected macaques were obtained through competition assays. The biodistributions of [⁸⁹Zr]Zr-7D3 and [⁸⁹Zr]Zr-ITS103.01LS-F(ab')₂ were performed with static PET scans up to 6 days post-injection in 20 rhesus macaques and the standardized uptake values in various tissues were compared between SIV-infected and uninfected controls.</p><p><strong>Results: </strong>Despite the demonstrated nanomolar affinity of [⁸⁹Zr]Zr-7D3 and [⁸⁹Zr]Zr-ITS103.01LS-F(ab')₂ to SIV gp120, and strong binding specificity to SIV gp120 cell lines, we observed no discernible differences in their binding in primary cells, tissue sections of secondary lymphoid organs, in-vivo probe uptake between SIV-infected and uninfected macaques, or ex-vivo validation necropsies. While the probes remained stable in-vivo, only [⁸⁹Zr]Zr-ITS103.01LS-F(ab')₂ in chronic plasma retained its binding specificity to SIV gp120, with [⁸⁹Zr]Zr-7D3 experiencing a > 97% reduction in binding to gp120 due to competition from endogenous antibodies at the 7D3 binding site.</p><p><strong>Conclusion: </strong>The overall absence of specific uptake suggests inadequate binding potential (ligand affinity x target molarity) for these probes to effectively image SIV or HIV in-vivo, warranting further investigation into the lack of reproducibility observed with earlier non-human primate SIV imaging and conflicting human studies.</p>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":" ","pages":"2645-2657"},"PeriodicalIF":8.6,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143064692","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Re: Chinese management guidelines for radioactive iodine-refractory differentiated thyroid cancer (2025 edition).","authors":"Petra Petranović Ovčariček, Murat Tuncel, Michael C Kreissl, Alfredo Campennì, Bart de Keizer, Désirée Deandreis, Luca Giovanella","doi":"10.1007/s00259-025-07367-z","DOIUrl":"https://doi.org/10.1007/s00259-025-07367-z","url":null,"abstract":"","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":" ","pages":""},"PeriodicalIF":8.6,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144173254","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Artificial intelligence-enabled opportunistic identification of immune checkpoint inhibitor-related adverse events using [¹⁸F]FDG PET/CT.","authors":"Clemens P Spielvogel, Aleksa Lazarevic, Lucia Zisser, David Haberl, Christophoros Eseroglou, Lucian Beer, Marcus Hacker, Raffaella Calabretta","doi":"10.1007/s00259-025-07364-2","DOIUrl":"https://doi.org/10.1007/s00259-025-07364-2","url":null,"abstract":"","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":" ","pages":""},"PeriodicalIF":8.6,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144173225","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Five-year follow-up of Estimabl 2 trail: a critical appraisal.","authors":"Murat Tuncel, Petra Petranovic Ovcaricek, Luca Giovanella","doi":"10.1007/s00259-025-07375-z","DOIUrl":"https://doi.org/10.1007/s00259-025-07375-z","url":null,"abstract":"","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":" ","pages":""},"PeriodicalIF":8.6,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144173251","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of PET vascular activity score with Takayasu's arteritis angiographic progression.","authors":"Sifan Wu, Bing Wu, Lingying Ma, Mengdi Li, Xianting Sun, Shuhui Zhang, Hongcheng Shi, Lindi Jiang","doi":"10.1007/s00259-025-07348-2","DOIUrl":"https://doi.org/10.1007/s00259-025-07348-2","url":null,"abstract":"<p><strong>Objective: </strong>Arterial wall Fluorodeoxyglucose (FDG) uptake can reflect vascular inflammation in Takayasu's arteritis (TAK); however, its association with vascular prognosis remains unclear. This study assessed the predictive efficacy of the PET vascular activity score (PETVAS) for vascular prognosis and whether FDG uptake in specific arterial territories was associated with angiographic progression in TAK.</p><p><strong>Methods: </strong>Patients with TAK from a prospective observational cohort who underwent ¹⁸F-FDG PET/CT and serological tests at baseline were included. Magnetic Resonance Angiography and/or Contrast-Enhanced Ultrasound were conducted at baseline and every six months during follow-up. The PETVAS was calculated. New/aggravated lesions were considered as angiographic progression.</p><p><strong>Results: </strong>The imaging evaluation included 1,353 arterial territories from 123 patients. The baseline PETVAS was positively correlated with Erythrocyte Sedimentation Rate (ESR), serum IL-6, and Platelet. Angiographic progression was noted in 45 patients (36.6%) with 72 territories (5.3%) during 30 (18-72) months of follow-up. Of these, 19 (42.2%) had baseline PETVAS > 15, including 84.2% (16/19) naïve cases and 78.9% (15/19) with ESR ≥ 30 mm/h. Multivariate Cox proportional hazards regression analysis adjusted for age and sex showed baseline PETVAS > 15 (HR 1.93; 95% CI, 1.01-3.68; p = 0.04) an independent predictor of angiographic progression.</p><p><strong>Conclusion: </strong>Baseline PETVAS > 15 was an independent predictor of angiographic progression in TAK. Baseline FDG uptake in specific arterial territories did not correlate with vascular progression. Our study provides a feasible PET/CT-based predictive marker for vascular progression in TAK and underscores the importance of regular imaging follow-up to monitor disease outcomes.</p><p><strong>Clinical trial number: </strong>Not applicable.</p>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":" ","pages":""},"PeriodicalIF":8.6,"publicationDate":"2025-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144157509","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}